Across TCGA pan-cancer cohorts, OR5T2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of OR5T2’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where OR5T2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types OR5T2 is over-expressed in tumor.
BRCA and LUAD are the cancer types where OR5T2 tumor–normal differential expression is most reproducible.